Lung Cancer: From Molecular Basis to Genome-Guided Therapy and Immunotherapy 2.0

Dear Colleagues,

In the last 15 years, lung cancer diagnosis and therapy underwent two game-changing revolutions. We witnessed the introduction of so-called “individualized” therapy driven by, in addition to more conventional tumor characteristics, a well-defined molecular phenotype from each tumor that serves as prognostic and much more predictive factors for the therapeutic faith of patients.

In only a short time, the therapeutic use of immune checkpoint inhibitors followed tailored therapeutic approaches, opening a new field of effective treatment for a remarkable proportion of lung cancer patients. The suitability criteria that must be treated following this approach, however, are not that well-defined and based on semiquantitative (merely classical) immunohistochemistry scoring.

Paying tribute to these 15 years of development, this Special Issue targets aims to share the state-of-the-art advances in biomarker-based lung cancer diagnosis and therapy, and its promising concepts for future developments. This clear focus is on the interface between molecular diagnosis and lung cancer therapy, thus all types of papers with a clear focus on the molecular alterations that influence the pathology and/or clinical aspects of lung cancer patients are welcomed.

Prof. Dr. Thomas Mairinger
Dr. Fabian Dominik Mairinger
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• lung cancer
• molecular pathology
• molecular diagnosis
• biomarker-driven therapy
• immunotherapy
• immune checkpoint inhibitors
• personalized tumor therapy
• cancer diagnosis